## Fabio Di Domenico

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3359570/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Oxidative stress and mTOR in Down syndrome brain: Link to Alzheimer's dysmetabolism, neuropathology, and possible therapies. , 2022, , 75-96.		0
2	Aberrant crosstalk between insulin signaling and mTOR in young Down syndrome individuals revealed by neuronalâ€derived extracellular vesicles. Alzheimer's and Dementia, 2022, 18, 1498-1510.	0.4	16
3	The Interplay Among Oxidative Stress, Brain Insulin Resistance and AMPK Dysfunction Contribute to Neurodegeneration in Type 2 Diabetes and Alzheimer Disease. Free Radical Biology and Medicine, 2022, 180, s105.	1.3	0
4	CAPE and its synthetic derivative VP961 restore BACH1/NRF2 axis in Down Syndrome. Free Radical Biology and Medicine, 2022, 183, 1-13.	1.3	9
5	Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: Insights for therapeutic intervention. Progress in Neurobiology, 2021, 196, 101892.	2.8	21
6	The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome. Neurotherapeutics, 2021, 18, 340-363.	2.1	12
7	Broad Kinase Inhibition Mitigates Early Neuronal Dysfunction in Tauopathy. International Journal of Molecular Sciences, 2021, 22, 1186.	1.8	6
8	Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules. Biomolecules, 2021, 11, 266.	1.8	19
9	Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: A harmful synergistic path in down syndrome. Free Radical Biology and Medicine, 2021, 165, 152-170.	1.3	26
10	High-Fat Diet Leads to Reduced Protein O-GlcNAcylation and Mitochondrial Defects Promoting the Development of Alzheimer's Disease Signatures. International Journal of Molecular Sciences, 2021, 22, 3746.	1.8	17
11	mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorder. Free Radical Biology and Medicine, 2021, 169, 382-396.	1.3	58
12	The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radical Biology and Medicine, 2021, 176, 16-33.	1.3	53
13	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /C	verlock 10 4.3	) Tf 50 262 T 1,430
14	Protein Oxidative Damage in UV-Related Skin Cancer and Dysplastic Lesions Contributes to Neoplastic Promotion and Progression. Cancers, 2020, 12, 110.	1.7	8
15	Proteomics Study of Peripheral Blood Mononuclear Cells in Down Syndrome Children. Antioxidants, 2020, 9, 1112.	2.2	5
16	BVR-A Deficiency Leads to Autophagy Impairment through the Dysregulation of AMPK/mTOR Axis in the Brain—Implications for Neurodegeneration. Antioxidants, 2020, 9, 671.	2.2	17
17	Aberrant protein Oâ€GlcNAcylation drives ADâ€like neurodegeneration in DS mice. Alzheimer's and Dementia, 2020, 16, e039361.	0.4	0
18	High fat diet leads to aberrant protein Oâ€GlcNAcylation and to the development of Alzheimer disease signatures in mice. Alzheimer's and Dementia, 2020, 16, e039449.	0.4	0

#	Article	IF	CITATIONS
19	Loss of biliverdin reductaseâ€a (BVRâ€A) impairs beneficial effects of CNS insulin on brain energy metabolism favoring the development of Alzheimer's disease (AD) neuropathology. Alzheimer's and Dementia, 2020, 16, e039511.	0.4	0
20	PERK inhibition promotes the rescue of protein translation and Nrf2â€related antioxidant response. Alzheimer's and Dementia, 2020, 16, e041867.	0.4	1
21	The Anti-Diabetic Drug Metformin Rescues Aberrant Mitochondrial Activity and Restrains Oxidative Stress in a Female Mouse Model of Rett Syndrome. Journal of Clinical Medicine, 2020, 9, 1669.	1.0	17
22	Multiple Herpes Simplex Virus-1 (HSV-1) Reactivations Induce Protein Oxidative Damage in Mouse Brain: Novel Mechanisms for Alzheimer's Disease Progression. Microorganisms, 2020, 8, 972.	1.6	17
23	Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome. Neurobiology of Disease, 2020, 137, 104772.	2.1	54
24	Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease. Molecular Neurobiology, 2019, 56, 2922-2943.	1.9	70
25	Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives. CNS Drugs, 2019, 33, 957-969.	2.7	45
26	Shining a light on defective autophagy by proteomics approaches: implications for neurodegenerative illnesses. Expert Review of Proteomics, 2019, 16, 951-964.	1.3	9
27	Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1490-1501.	1.8	29
28	Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome. Redox Biology, 2019, 23, 101162.	3.9	46
29	Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease. Neurobiology of Disease, 2019, 125, 176-189.	2.1	55
30	Therapeutic potential of rescuing protein O-GlcNAcylation in tau-related pathologies. Expert Review of Neurotherapeutics, 2019, 19, 1-3.	1.4	15
31	Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models. Journal of Alzheimer's Disease, 2018, 62, 347-359.	1.2	19
32	mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia. Free Radical Biology and Medicine, 2018, 114, 94-101.	1.3	72
33	Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome. Translational Neurodegeneration, 2018, 7, 28.	3.6	76
34	Protein nitration profile of CD3+ lymphocytes from Alzheimer disease patients: Novel hints on immunosenescence and biomarker detection. Free Radical Biology and Medicine, 2018, 129, 430-439.	1.3	20
35	Biliverdin reductase-A impairment links brain insulin resistance with increased Aβ production in an animal model of aging: Implications for Alzheimer disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3181-3194.	1.8	49
36	Poly-ubiquitin profile in Alzheimer disease brain. Neurobiology of Disease, 2018, 118, 129-141.	2.1	29

## **FABIO DI DOMENICO**

#	Article	IF	CITATIONS
37	Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3309-3321.	1.8	29
38	Identification of changes in neuronal function as a consequence of aging and tauopathic neurodegeneration using a novel and sensitive magnetic resonance imaging approach. Neurobiology of Aging, 2017, 56, 78-86.	1.5	23
39	Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders. Free Radical Biology and Medicine, 2017, 111, 253-261.	1.3	190
40	Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies. Expert Review of Neurotherapeutics, 2017, 17, 33-45.	1.4	55
41	The Triangle of Death in Alzheimer's Disease Brain: The Aberrant Cross-Talk Among Energy Metabolism, Mammalian Target of Rapamycin Signaling, and Protein Homeostasis Revealed by Redox Proteomics. Antioxidants and Redox Signaling, 2017, 26, 364-387.	2.5	97
42	Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology. Antioxidants and Redox Signaling, 2017, 26, 280-298.	2.5	38
43	[P4–032]: BILIVERDIN REDUCTASEâ€A MEDIATES THE BENEFICIAL EFFECTS OF INTRANASAL INSULIN ADMINISTRATION ON AD PATHOLOGY IN THE BRAIN OF 3XTGâ€AD MICE. Alzheimer's and Dementia, 2017, 13, P1267.	0.4	0
44	It Is All about (U)biquitin: Role of Altered Ubiquitin-Proteasome System and UCHL1 in Alzheimer Disease. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-12.	1.9	88
45	Introductory Editorial: Drug-Eluting Stents or Drug-Eluting Grafts? Insights from Proteomic Analysis. Drug Target Insights, 2016, 10s1, DTI.S41240.	0.9	6
46	Improvement of BVR-A Activity Ameliorates Brain Insulin Resistance in Alzheimer Disease Following Intranasal Insulin Administration. Free Radical Biology and Medicine, 2016, 100, S157-S158.	1.3	0
47	Redox proteomic analysis of serum from aortic anerurysm patients: insights on oxidation of specific protein target. Molecular BioSystems, 2016, 12, 2168-2177.	2.9	4
48	Aberrant protein phosphorylation in Alzheimer disease brain disturbs pro-survival and cell death pathways. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1871-1882.	1.8	73
49	Cathepsin D as a therapeutic target in Alzheimer's disease. Expert Opinion on Therapeutic Targets, 2016, 20, 1393-1395.	1.5	41
50	Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype. Journal of Alzheimer's Disease, 2016, 52, 359-371.	1.2	35
51	Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: A new paradigm. Free Radical Biology and Medicine, 2016, 91, 127-142.	1.3	98
52	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
53	Increased Mammalian Target of Rapamycin Signaling Contributes to the Accumulation of Protein Oxidative Damage in a Mouse Model of Down's Syndrome. Neurodegenerative Diseases, 2016, 16, 62-68.	0.8	35
54	Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients. Free Radical Biology and Medicine, 2016, 91, 1-9.	1.3	74

**FABIO DI DOMENICO** 

#	Article	IF	CITATIONS
55	Redox Proteomics in Human Biofluids: Sample Preparation, Separation and Immunochemical Tagging for Analysis of Protein Oxidation. Methods in Molecular Biology, 2016, 1303, 391-403.	0.4	7
56	Autoantibodies Profile in Matching CSF and Serum from AD and aMCI patients: Potential Pathogenic Role and Link to Oxidative Damage. Current Alzheimer Research, 2016, 13, 112-122.	0.7	15
57	Oxidative Signature of Cerebrospinal Fluid from Mild Cognitive Impairment and Alzheimer Disease Patients. Free Radical Biology and Medicine, 2015, 87, S146.	1.3	Ο
58	Basal brain oxidative and nitrative stress levels are finely regulated by the interplay between superoxide dismutase 2 and p53. Journal of Neuroscience Research, 2015, 93, 1728-1739.	1.3	18
59	Pharmacologic approaches against Advanced Glycation End Products (AGEs) in diabetic cardiovascular disease. Research in Cardiovascular Medicine, 2015, 4, 5.	0.2	50
60	Aberrant insulin signaling in Alzheimer's disease: current knowledge. Frontiers in Neuroscience, 2015, 9, 204.	1.4	229
61	Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with preâ€clinical AD, amnestic mild cognitive impairment and lateâ€stage AD. Journal of Neurochemistry, 2015, 133, 739-749.	2.1	276
62	Bach1 Overexpression in Down Syndrome Correlates with the Alteration of the HO-1/BVR-A System: Insights for Transition to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 1107-1120.	1.2	53
63	mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiology of Disease, 2015, 84, 39-49.	2.1	261
64	Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants. Expert Review of Neurotherapeutics, 2015, 15, 19-40.	1.4	87
65	Pharmacologic approaches against Advanced Glycation End Products (AGEs) in diabetic cardiovascular disease. Research in Cardiovascular Medicine, 2015, 4, 5.	0.2	1
66	Oxidative Stress and Proteostasis Network: Culprit and Casualty of Alzheimer's-Like Neurodegeneration. Advances in Geriatrics, 2014, 2014, 1-14.	1.6	36
67	Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: Insights from proteomics. Proteomics - Clinical Applications, 2014, 8, 73-85.	0.8	52
68	Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Free Radical Biology and Medicine, 2014, 71, 270-280.	1.3	87
69	Simvastatin attenuates the endothelial pro-thrombotic shift in saphenous vein grafts induced by Advanced glycation endproducts. Thrombosis Research, 2014, 133, 418-425.	0.8	10
70	Statins more than cholesterol lowering agents in Alzheimer disease: Their pleiotropic functions as potential therapeutic targets. Biochemical Pharmacology, 2014, 88, 605-616.	2.0	73
71	Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. Biochemical Journal, 2014, 463, 177-189.	1.7	93
72	Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1693-1706.	1.8	286

**ΓΑΒΙΟ DI DOMENICO** 

#	Article	IF	CITATIONS
73	Mass spectrometry and redox proteomics: Applications in disease. Mass Spectrometry Reviews, 2014, 33, 277-301.	2.8	98
74	Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1144-1153.	1.8	127
75	The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: It's time for reconciliation. Neurobiology of Disease, 2014, 62, 144-159.	2.1	109
76	Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: Redox proteomics analysis of human brain. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1249-1259.	1.8	109
77	Proteomics strategies to analyze HPV-transformed cells: relevance to cervical cancer. Expert Review of Proteomics, 2013, 10, 461-472.	1.3	12
78	Usefulness of Preprocedural Levels of Advanced Glycation End Products to Predict Restenosis in Patients With Controlled Diabetes Mellitus Undergoing Drug-Eluting Stent Implantation for Stable Angina Pectoris (From the Prospective ARMYDA-AGEs Study). American Journal of Cardiology, 2013, 112, 21-26.	0.7	18
79	Involvement of Oxidative Stress in Occurrence of Relapses in Multiple Sclerosis: The Spectrum of Oxidatively Modified Serum Proteins Detected by Proteomics and Redox Proteomics Analysis. PLoS ONE, 2013, 8, e65184.	1.1	73
80	Peripheral Biomarkers of Oxidative Stress in Alzheimer's Disease. Oxidative Stress in Applied Basic Research and Clinical Practice, 2013, , 185-199.	0.4	0
81	Biliverdin Reductase-A correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain. Neural Regeneration Research, 2013, 8, 1925-37.	1.6	11
82	HO-1/BVR-A System Analysis in Plasma from Probable Alzheimer's Disease and Mild Cognitive Impairment Subjects: A Potential Biochemical Marker for the Prediction of the Disease. Journal of Alzheimer's Disease, 2012, 32, 277-289.	1.2	43
83	Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. International Journal of Neuropsychopharmacology, 2012, 15, 981-987.	1.0	63
84	Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: Insights from redox proteomics. Free Radical Biology and Medicine, 2012, 53, 1868-1876.	1.3	59
85	Analysis of HO-1/BVR post translational modifications as potential plasma biomarker of Alzheimer's disease (AD) pathology. Free Radical Biology and Medicine, 2012, 53, S172.	1.3	О
86	Lack of p53 Decreases Basal Oxidative Stress Levels in the Brain Through Upregulation of Thioredoxin-1, Biliverdin Reductase-A, Manganese Superoxide Dismutase, and Nuclear Factor Kappa-B. Antioxidants and Redox Signaling, 2012, 16, 1407-1420.	2.5	30
87	Inhibition of lipid peroxidation and protein oxidation by endogenous and exogenous antioxidants in rat brain microsomes in vitro. Neuroscience Letters, 2012, 518, 101-105.	1.0	72
88	Antioxidants in cervical cancer: Chemopreventive and chemotherapeutic effects of polyphenols. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 737-747.	1.8	107
89	Sex differences in brain proteomes of neuronâ€specific STAT3â€null mice after cerebral ischemia/reperfusion. Journal of Neurochemistry, 2012, 121, 680-692.	2.1	29
90	Serum proteomics in patients with diagnosis of abdominal aortic aneurysm. Cardiovascular Pathology, 2012, 21, 283-290.	0.7	17

**ΓΑΒΙΟ DI DOMENICO** 

#	Article	IF	CITATIONS
91	Redox Proteomics Analyses of the Influence of Co-Expression of Wild-Type or Mutated LRRK2 and Tau on C. elegans Protein Expression and Oxidative Modification: Relevance to Parkinson Disease. Antioxidants and Redox Signaling, 2012, 17, 1490-1506.	2.5	43
92	Oxidative Stress in HPV-Driven Viral Carcinogenesis: Redox Proteomics Analysis of HPV-16 Dysplastic and Neoplastic Tissues. PLoS ONE, 2012, 7, e34366.	1.1	63
93	Biliverdin reductaseâ€A: a novel drug target for atorvastatin in a dog preâ€clinical model of Alzheimer disease. Journal of Neurochemistry, 2012, 120, 135-146.	2.1	63
94	Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radical Biology and Medicine, 2012, 52, 2292-2301.	1.3	108
95	Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: A novel mechanism of action. Pharmacological Research, 2011, 63, 172-180.	3.1	86
96	Biliverdin reductase-A protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 480-487.	1.8	77
97	Circulating biomarkers of protein oxidation for Alzheimer disease: Expectations within limits. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 1785-1795.	1.1	56
98	Proteomic identification of specifically carbonylated brain proteins in APPNLh/APPNLh×PS-1P264L/PS-1P264L human double mutant knock-in mice model of Alzheimer disease as a function of age. Journal of Proteomics, 2011, 74, 2430-2440.	1.2	36
99	Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid. Proteomics - Clinical Applications, 2011, 5, 167-178.	0.8	86
100	Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects. Journal of Proteomics, 2011, 74, 1091-1103.	1.2	86
101	Oxidative and Nitrosative Modifications of Biliverdin Reductase-A in the Brain of Subjects with Alzheimer's Disease and Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2011, 25, 623-633.	1.2	85
102	Oxidative Damage in Rat Brain During Aging: Interplay Between Energy and Metabolic Key Target Proteins. Neurochemical Research, 2010, 35, 2184-2192.	1.6	53
103	Effects of UVB-induced oxidative stress on protein expression and specific protein oxidation in normal human epithelial keratinocytes: a proteomic approach. Proteome Science, 2010, 8, 13.	0.7	64
104	Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: An investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Research, 2010, 1333, 72-81.	1.1	94
105	Involvement of stat3 in mouse brain development and sexual dimorphism: A proteomics approach. Brain Research, 2010, 1362, 1-12.	1.1	21
106	Redox proteomics in aging rat brain: Involvement of mitochondrial reduced glutathione status and mitochondrial protein oxidation in the aging process. Journal of Neuroscience Research, 2010, 88, 3498-3507.	1.3	99
107	The wheat germ agglutininâ€fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: Implications for disease pathogenesis and progression. Journal of Neuroscience Research, 2010, 88, 3566-3577.	1.3	34
108	Doxorubicin-Induced Thymus Senescence. Journal of Proteome Research, 2010, 9, 6232-6241.	1.8	25

## FABIO DI DOMENICO

#	Article	IF	CITATIONS
109	Proteomics analysis of protein expression and specific protein oxidation in human papillomavirus transformed keratinocytes upon UVB irradiation. Journal of Cellular and Molecular Medicine, 2009, 13, 1809-1822.	1.6	23
110	Advanced glycation end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: possible implications in venous graft failure. Diabetes/Metabolism Research and Reviews, 2009, 25, 420-426.	1.7	19
111	Glutathionylation of the Pro-apoptotic Protein p53 in Alzheimer's Disease Brain: Implications for AD Pathogenesis. Neurochemical Research, 2009, 34, 727-733.	1.6	72
112	Redox proteomics identification of 4â€hydroxynonenalâ€modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics - Clinical Applications, 2009, 3, 682-693.	0.8	172
113	Proteomics-Determined Differences in the Concanavalin-A-Fractionated Proteome of Hippocampus and Inferior Parietal Lobule in Subjects with Alzheimer's Disease and Mild Cognitive Impairment: Implications for Progression of AD. Journal of Proteome Research, 2009, 8, 471-482.	1.8	91
114	Expression of human papilloma virus type 16 E5 protein in amelanotic melanoma cells regulates endo-cellular pH and restores tyrosinase activity. Journal of Experimental and Clinical Cancer Research, 2009, 28, 4.	3.5	15
115	Protective effect of ferulic acid ethyl ester against oxidative stress mediated by UVB irradiation in human epidermal melanocytes. Free Radical Research, 2009, 43, 365-375.	1.5	38
116	Proteomic analysis for the study of amniotic fluid protein composition. Journal of Prenatal Medicine, 2009, 3, 39-41.	0.2	7